Enhancement of pacing function by HCN4 overexpression in human pluripotent stem cell-derived cardiomyocytes

Yukihiro Saito1*, Kazufumi Nakamura2*, Masashi Yoshida3, Hiroki Sugiyama4, Satoshi Akagi2, Toru Miyoshi2, Hiroshi Morita5 and Hiroshi Ito2

Abstract

Background: The number of patients with bradyarrhythmia and the number of patients with cardiac pacemakers are increasing with the aging population and the increase in the number of patients with heart diseases. Some patients in whom a cardiac pacemaker has been implanted experience problems such as pacemaker infection and inconvenience due to electromagnetic interference. We have reported that overexpression of HCN channels producing a pacemaker current in mouse embryonic stem cell-derived cardiomyocytes showed enhanced pacing function in vitro and in vivo. The aim of this study was to determine whether HCN4 overexpression in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) can strengthen the pacing function of the cells.

Methods: Human HCN4 was transduced in the AAVS1 locus of human induced pluripotent stem cells by nucleofection and HCN4-overexpressing iPSC-CMs were generated. Gene expression profiles, frequencies of spontaneous contraction and pacing abilities of HCN4-overexpressing and non-overexpressing iPSC-CMs in vitro were compared.

Results: HCN4-overexpressing iPSC-CMs showed higher spontaneous contraction rates than those of non-overexpressing iPSC-CMs. They responded to an HCN channel blocker and β-adrenergic stimulation. The pacing rates against parent iPSC line-derived cardiomyocytes were also higher in HCN4-overexpressing iPSC-CMs than in non-overexpressing iPSC-CMs.

Conclusions: Overexpression of HCN4 showed enhancement of If current, spontaneous firing and pacing function in iPSC-CMs. These data suggest this transgenic cell line may be useful as a cardiac pacemaker.

Keywords: Hyperpolarization-activated cyclic nucleotide-gated potassium channel 4, Human induced pluripotent stem cell-derived cardiomyocytes, Pacing

Introduction

The number of patients with bradyarrhythmia is increasing with the increase in the number of patients with heart diseases associated with aging. The treatment for bradyarrhythmia is mechanical pacemaker implantation, but there are remaining issues such as battery replacement due to battery drain, infection, electromagnetic interference and rate response. Biological pacemakers generated by gene transfer or cell transplantation are expected to be used as a new treatment for resolving these problems.
TBX18 gene transduction by an adenoviral vector has been shown to convert ventricular myocytes into sinoatrial node-like cells in vitro and in vivo. [1, 2] However, adenoviral vector-based gene therapy decays over time because adenoviral vectors are suitable for transient high expression and have immunogenicity that causes immune cells to eliminate reprogrammed cells. Therefore, this method is useful for temporary pacing but not for long-term use.

Several methods for the induction of sinoatrial node-like pacemaker cells derived from human pluripotent stem cells (PSCs) have been reported. Yechikov et al. [3] increased the induction efficiency of sinoatrial node-like cells from 10–15% to 20–30% by adding a TGFβ receptor inhibitor, SB431542, in addition to the Wnt inhibitor IWR1 after cardiac mesoderm induction during cardiac induction of human induced pluripotent stem cells (iPSCs). Protze et al. [4] found that NKX2-5-negative cells among cardiomyocytes induced by BMP4 and Activin A from human embryonic stem cells (ESCs) exhibited sinoatrial node-like gene expression patterns. Furthermore, they described a method in which 80% of the induced cardiomyocytes become sinoatrial node-like cells when BMP4, retinoic acid, and FGF receptor inhibitor (PD173074), and SB431542 were added in addition to a Wnt inhibitor during the cardiac mesoderm stage. Although this method is very useful, it is likely that the concentrations of various growth factors and inhibitors need to be adjusted for each cell line. Liu et al. [5] reported that the induction efficiency of sinoatrial node-like cells was 40–50% by adding BMP4, PD173074, and a retinoic acid receptor inhibitor, BMS189453, during the cardiac progenitor stage. Liang et al. [6] found that 70% of the induced cardiomyocytes were sinoatrial node-like cells by removing the Wnt inhibitor after mesoderm induction, but the cardiomyocyte yield was as low as 20%. Pezhouman et al. [7] reported that adjustments of the cell seeding density and the concentration of a GSK3 inhibitor, CHIR99021, during mesoderm induction resulted in the generation of NKX2-5-negative TBX5-positive cardiac progenitor cells that gave rise to podoplanin-positive sinoatrial node-like cells with high efficiency. However, no functional analysis has been performed. Zhao et al. [8] transduced TBX3 with a lentiviral vector during the cardiac mesoderm stage, but the proportion of sinoatrial node-like cells was only 20%. For each method, there is room for improvement in induction efficiency, yield and simplicity.

Recently, designer cells with functions added by genetic modification, such as cells used in chimeric antigen receptor (CAR) T-cell therapy, are expected to become new tools for cell-based therapy [9, 10]. Previously, we have transduced HCN4 into mouse embryonic stem cell-derived cardiomyocytes (ESC-CMs) to intensify their pacing function in vitro and in vivo [11, 12]. HCN4 encodes a hyperpolarization-activated cyclic nucleotide-gated potassium channel (HCN channel) producing a pacemaker current. It has been reported that human PSC-derived cardiomyocytes (PSC-CMs) express HCN4 and have some pacing potency that would be lost along maturation [13–16]. HCN4 overexpression seems simpler than other methods to generate pacemaker cells from human PSCs, however, this strategy have not been tested with human PSCs. In addition, the electrophysiological properties are different between rodent cardiomyocytes and human cardiomyocytes [17]. In this study, we investigated whether HCN4 overexpression in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) improves pacemaker function in vitro.

**Methods**

**Method summary**

The strategy to generate HCN4-overexpressing iPSC-CMs is summarized in Fig. 1.

**Donor plasmid vector construction**

The sequences of “CAG promoter_IRES_EGFP_polyA” in pCAGIG (Cat#. 11159, Addgene, Watertown, MA, United states), “splice acceptor (SA)_loxP_PGK promoter_neomycin resistance gene (Neo)_loxP” in
pRosa26-DEST (Cat#. 21189, Addgene) and “AAVS1 3’ homology arm_Ampicillin resistance gene (AmpR)_AAVS1 5’ homology arm” in AAV-CAGGS-EGFP (Cat#. 22212, Addgene) were amplified by the polymerase chain reaction (PCR) with PrimeSTAR GXL DNA polymerase (Cat#. R050A, Takara bio, Shiga, Japan), purified using a QIAquick PCR Purification Kit (Cat#. 28104, Qiagen, Hilden, Germany), and then ligated with an In-fusion HD enzyme (Cat#. 639648, Clontech, Mountain View, CA, United States) to get the control donor vector, “pAAVS1_SA_loxP_PGK_Neo_loxP/CAG_ IRES_EGFP/AmpR”. Human HCN4 open reading frame (ORF) subcloned into pCMV6-XL5 vector (Cat#. SC303651) was purchased from Origene (Rockville, MD, United States). HCN4 ORF was amplified by PCR, purified, and ligated with an Xho I-digested control donor vector to get “pAAVS1_SA_loxP_PGK_Neo_loxP/CAG_HCN4_IRES_EGFP/AmpR”. PCR primers are shown in Table 1.

### Cell culture

Human iPSCs generated from dermal fibroblasts obtained from a healthy subject with retroviral vectors were used in this study [11, 18]. The cells were dissociated with StemPro Accutase Cell Dissociation Reagent.

### Table 1  PCR primers

| Name       | Sequence                                                                 | Product size (bp) | Annealing temperature (°C) |
|------------|---------------------------------------------------------------------------|-------------------|---------------------------|
| Subcloning PCR |
| PGK-Neo    | Forward TGGGCGCGGATCTGATGGGCAGCAGTA                                        | 2886              | 64                        |
|            | Reverse AACTAGATAACTTCTGATACATACATTACGAGAAT                                 |                   |                           |
| AAVS1 homology arm/AmpR |
| Forward   | ACCCGAGACTAGGGGACGATTG                                                  | 5624              | 64                        |
| Reverse   | ACAGATCGCGCCACTGTGGGGTGGA                                               |                   |                           |
| CAG-IRES-EGFP |
| Forward   | CGAAGTTATCTGATTTATATAGTAATATATTACGACG                                      | 3614              | 62                        |
| Reverse   | CCGTACTGCTCAGTGACGGAGAT                                                  |                   |                           |
| Human HCN4 |
| Forward   | CAAAGAATACCTCGAGACCGACAGTGGCAAGTCCGAGTCGAC                                 | 3647              | 64                        |
| Reverse   | CCGCAGATATCCCTCGAGTCATAGATTGGAGATGCGTGCAGC                               |                   |                           |
| Flanking PCR |
| Primer 1  | TGGCGCTTACCCACCTATGCTGCA                                                  |                   | 64                        |
| Primer 2  | ACAAGACGAAGAACGCGCATACAGG                                                  |                   |                           |
| Primer 3  | ACCAACCACATTCCTGGTTTCCATGAGACTGA                                         |                   |                           |
| qPCR      |
| GAPDH     | Forward CAACGAGACCTTCTGATAGGC                                             | 144               | 60                        |
| Reverse   | TCTCTCTCTCTGCTGCTGCTG                                                    |                   |                           |
| HCN4      | Forward GTGGTCATCACAAACATGG                                               | 121               | 60                        |
| Reverse   | GCCTTGAGAGCGCGTAG                                                        |                   |                           |
| MYL2      | Forward GTGCTGAAGGCGATAGGC                                               | 121               | 60                        |
| Reverse   | TGTAGTCAAGTTGCGAGGC                                                 |                   |                           |
| NRX2-5    | Forward GTCTCTGGATTTGGCATCC                                              | 100               | 60                        |
| Reverse   | ATATGCAGCGCACAAGCCTC                                                      |                   |                           |
| NR2F2     | Forward TGGGCTTATGAGCAGCAG                                               | 149               | 60                        |
| Reverse   | TCCCATGGCGCTACGAG                                                        |                   |                           |
| SCN5A     | Forward AGAAGATGTGAGGCCCCAGGAGC                                           | 131               | 60                        |
| Reverse   | AACTCTGCTCTGAGACCCAGGTC                                                   |                   |                           |
| SHOX2     | Forward ATCGCAAGGAAGGATCGAGC                                              | 86                | 60                        |
| Reverse   | TCCAGGGTAAGTTGTGCGAG                                                     |                   |                           |
| TBX3      | Forward TTAAGACCATGAGGCCCCAGGAG                                           | 91                | 60                        |
| Reverse   | CCCGTCCTGTAAGCTGTCAG                                                     |                   |                           |
| TBX18     | Forward TTAACCTTGTGCTGCTGCTGAG                                            | 147               | 60                        |
| Reverse   | GAACTGGCTTGGCAGGGCTGCTGAG                                                  |                   |                           |
| TNNT2     | Forward TTCACCAGGACATCTGCTTGGCTGCT                                       | 166               | 60                        |
| Reverse   | TTATCTGGTGTGGAGGCGTGTGG                                                   |                   |                           |
(Cat#. A1110501, Thermo Fisher Scientific, Waltham, MA, United States). Then they were resuspended in StemFit AK02N (Cat#. AK02N, Ajinomoto Healthy Supply, Tokyo, Japan) with 10 µmol/L Y-27632 (Cat#. S1049, Selleck chemicals, Houston, TX, United States) and seeded at 1.5 × 10^5/cm^2 on 0.25 µg/cm^2 iMatrix-511 silk (Cat#. 892021, Matrixome, Osaka, Japan)-coated 6-well plates (Cat#. 3516, Corning, Corning, NY, United States) [19]. The medium was changed with StemFit without Y-27632 the next day and cells were passage once a week.

**Nucleofection**

Human iPSCs were harvested using StemPro Accutase Cell Dissociation Reagent. Ten µg of a non-linearized donor vector, 5 µg of AAVS1 1L TALEN (Cat#. 35431, Addgene) and 5 µg of AAVS1 1R TALEN (Cat#. 35432, Addgene) were transduced with a Nucleofector II/Program B-016 (Cat#. AAD-1001N, Amaza Biosystems, Nordrhein-Westfalen, Germany) and an Amaza Human Stem Cell Nucleofector Kit 1 (Cat#. VAPH-5012, Lonza, Basel, Switzerland). The cells were treated with 50 µg/ml G-418 (Cat#. 4727787001, Roche Applied Science, Penzberg, Germany) for 10 days. EGFP-positive clones were picked up and expanded on iMatrix-511-coated plates in StemFit AK02N. The established clones were genotyped by PCR. PCR primers are shown in Table 1.

**Cardiac differentiation of human iPSCs**

Our cardiac differentiation protocol was based on that previously reported by Lian et al.[20]. Human iPSCs were dissociated into single cells with StemPro Accutase Cell Dissociation Reagent and seeded on 0.5 µg/cm^2 iMatrix-511 silk-coated 12-well plates (Cat#. 3513, Corning) at 3 × 10^5/cm^2 in StemFit AK02N supplemented with 10 µmol/L Y-27632. The medium was changed with a medium without Y-27632 every day. Four days after plating, at day 0, cells were treated with 6 µmol/L CHIR99021 (Cat#. S2924, Selleck chemicals) in RMPI 1640 (Cat#. 11875093, Thermo Fisher Scientific) supplemented with B-27 supplement minus insulin (Cat#. A1895601, Thermo Fisher Scientific). After 24 h, at day 1, the medium was changed to RPMI supplemented with B-27 supplement minus insulin and 100 µmol/L ascorbic acid 2-glucoside (Cat#. AG121, Hayashibara, Okayama, Japan). On day 3, the medium was changed to RPMI supplemented with B-27 supplement minus insulin and 5 µmol/L IWP2 (Cat#. S7085, Selleck chemicals). On day 5, the medium was changed to RPMI supplemented with B-27 supplement minus insulin. From day 7, the medium was changed every 2 or 3 days. On day 12, the medium was changed to DMEM, no glucose (Cat#. 11966025, Thermo Fisher Scientific) supplemented with 16 mM L-(+)-lactic acid (Cat#. L1750, Merck, Kenilworth, NJ, United States) to remove non-cardiomyocytes [21]. Until day 19, the medium was changed every 2 or 3 days. After cardiomyocyte purification, the cells were maintained in RPMI supplemented with B-27 supplement (Cat#. 17504044, Thermo Fisher Scientific).

**Quantitative PCR**

Total RNA from iPSC-CMs was extracted using Trizol Reagent (Cat#. 15596026, Thermo Fisher Scientific) and PureLink RNA Mini Kit (Cat#. 12183018A, Thermo Fisher Scientific). Complementary DNA was synthesized from 500 ng of total RNA using SuperScript IV VILO Master Mix (Cat#. 11756050, Thermo Fisher Scientific) according to the manual and subjected to PCR amplification. PowerUp SYBR Green Master Mix (Cat#. A25742, Thermo Fisher Scientific) and Quantistudio 1 Real-Time PCR System (Cat#. Q5, Thermo Fisher Scientific) were used for quantitative PCR (qPCR). Quantitative PCR experiments were performed in duplicate. The qPCR data were processed by the ΔΔCT method. PCR primers are shown in Table 1.

**Transmission electron microscopy (TEM)**

HCN4-overexpressing iPSC-CMs were seeded on a Matrigel-coated 35 mm dish. The cells were fixed by chemical fixation and TEM was performed by Tokai Electron Microscopy (Aichi, Japan).

**Immunofluorescence**

The purified iPSC-CMs were plated on 0.5 µg/cm^2 iMatrix-511 silk-coated plates, fixed in 4% paraformaldehyde (Cat#. 09154-85, Nakalai tesque, Kyoto, Japan), permeabilized with 0.1% Triton X-100/ phosphate-buffered saline (PBS), and blocked with 10% goat serum and 0.1% Triton X-100/ PBS (Cat#. G9023, Merck). The cells were stained overnight at 4°C with primary antibodies against-α-actinin (1:1000 dilution, Cat#. A7811, Merck), cardiac Troponin T (1:16,000 dilution, Cat#. GTX28295, GeneTex, Irvine, CA, United States), NKX2-5 (1:2500 dilution, Cat#. sc-58622, Santa Cruz Biotechnology, Dallas, TX, United States), and Connexin 43 (1:500 dilution, Cat#. 8929S, Cell Signaling Technology, Danvers, MA), and Connexin 43 (1:500 dilution, Cat#. 83649, Cell Signaling Technology). Secondary antibodies were iFluor™ 488 goat anti-mouse IgG (H+L), iFluor™ 555 goat anti-mouse IgG (H+L), iFluor™ 488 goat anti-rabbit IgG (H+L), iFluor™ 555 goat anti-rabbit IgG (H+L) (1:1000 dilution, Cat#. 16528, 16540, 16678, 16690, AAT Bioquest, Sunnyvale, CA, United States) and Alexa Fluor 555 goat anti-rat IgG (H+L) (1:1000 dilution, ab150158, Abcam, Cambridge, United Kingdom). Nucleus staining was performed with Hoechst 33,342 (1:10,000 dilution, Cat#. H3570, Thermo Fisher Scientific). Plasma
membrane staining was performed with Wheat Germ Agglutinin, Alexa Fluor™ 350 Conjugate (Cat#. W11263, Thermo Fisher Scientific).

**Electrophysiology**
The perforated patch-clamp technique was performed using an Axopatch 200B amplifier (Molecular Devices, San Jose, CA, United States) and data were acquired with pClamp10.2/Clampfit (Molecular Devices). Cardiomyocytes were dissociated using TrypLE Select Enzyme (10X) (Cat#. A1217701) for 15 min, resuspended in RPMI 1640 supplemented with 20% fetal bovine serum and replated on Matrigel (Cat#. 354277, Corning)-coated cover glasses and incubated for 72 h. The cells were superfused with a bath solution containing (in mM): 132 NaCl, 4.8 KCl, 1.2 CaCl₂, 1.0 BaCl₂, 2.0 MnCl₂, 5.0 D-glucose, and 10 Heps; pH 7.4. Pipettes (2–4 MΩ resistances) were filled with a pipette solution containing (in mM): 110 K-aspartate, 5.0 K₂-ATP, 11 EGTA, 1.0 CaCl₂, 1 MgCl₂, and 5 Heps; pH 7.2. Then 0.3 mg/mL 110 DL-aspartic acid, 30 KCl, 1 CaCl₂, 5 ATP-Mg, 5 Creatine P-Na, 5 HEPES, and 10 EGTA; pH 7.25 (KOH). To activate patch perforation (series resistance: 10–20 MΩ; series resistance). The I_c current was activated by an standard activation protocol. I_c currents through activated HCN channels were obtained during hyperpolarizing test pulses of 5 s between −45 and −125 mV in 20-mV increments from a holding potential of −35 mV. Action potentials were measured using a modified Tyrode’s solution containing (in mM): 140 NaCl, 5.4 KCl, 1.8 CaCl₂, 1.0 MgCl₂, 5.5 glucose, and 5.0 HEPES; pH 7.4 (NaOH). The pipette solution contained (in mM) 110 DL-aspartic acid, 30 KCl, 1 CaCl₂, 5 ATP-Mg, 5 Creatine P-Na, 5 HEPES, and 10 EGTA; pH 7.25 (KOH). To achieve patch perforation (series resistance: 10–20 MΩ), amphotericin B (0.3 mg/mL) was added to the pipette solution. The temperature was maintained at 35–36 °C by a TC-344B dual channel heating system (Warner Instruments, Holliston, MA, United States).

**Counting frequencies of spontaneous beating**
The purified cardiomyocytes were plated on 0.25 µg/cm² iMatrix-511 silk-coated plates at 1 × 10⁷/cm² in RPMI 1640 with B-27 supplement and incubated for 4 days. We counted spontaneous eating frequencies for 15 s with an optical microscope and examined responses to 10 µmol/L ivabradine (Cat#. SML0281, Merck) and 1 µmol/L isoproterenol (Cat#. 15627, Merck).

**Counting contraction frequencies of EGFP-negative iPSC-CMs paced by EGFP-positive iPSC-CMs**
The center of each well of 12-well plates was coated with 30 µL PBS containing 0.5 µg iMatrix-511 silk. Next day, 4 × 10⁵ EGFP-positive iPSC-CMs were resuspended in 30 µL RPMI 1640 with B-27 supplement, 10 µmol/L Y27632 and 5% fetal bovine serum (Cat#. F7524, Merck) and then seeded on the iMatrix-511-coated area (day 0). On day 1, 1 mL/well RPMI 1640 with B-27 supplement was added. On day 3, the medium was changed to RPMI 1640 with B-27 supplement and 1 µg/well iMatrix-511 silk. On day 4, 4 × 10⁵ EGFP-negative parent iPSC-derived cardiomyocytes were resuspended in 1 mL RPMI 1640 with B-27 supplement, 10 µmol/L Y27632 and 5% fetal bovine serum and seeded on 12-well plates containing EGFP-positive cardiomyocytes. On day 5, the medium was changed to RPMI 1640 with B-27 supplement. On day 7, synchronized beating rates for 15 s of EGFP-negative iPSC-CMs away from the EGFP-positive area were counted with an optical microscope.

**Statistical analysis**
All data are expressed as means ± standard deviation. Statistical analysis was performed by Student’s t-test for unpaired data or one-way ANOVA with comparison of different groups by Dunnett’s post hoc test using SPSS ver. 24. Values of P < 0.05 were considered significant.

**Results**
**Generation of HCN4-overexpressing human iPSCs**
Human HCN4 ORF was inserted with TALEN in the AAVS1 region, where the transgene is less susceptible to silencing during differentiation [22, 23]. Homologous recombination into the AAVS1 region was confirmed by PCR (Fig. 2A). Despite overexpression of HCN4, iPSC cells expressed undifferentiated markers (OCT4, SSEA-4, TRA-1-60 and TRA-1-81) (Fig. 2B) and showed a typical morphology (Fig. 2C).

**Induction of HCN4-overexpressing cardiomyocytes**
Cardiomyocytes were efficiently induced from HCN4-overexpressing iPSCs with a commonly used cardiac differentiation protocol using a GSK3 inhibitor and a Wnt inhibitor (Additional file 1). Electron micrographs showed muscle fibers and mitochondria, which were consistent with cardiomyocytes (Fig. 3A). Overexpression of HCN4 protein was confirmed by immunostaining (Fig. 3B). EGFP expression indicating transgene expression was detected in cardiomyocytes 100 days after differentiation (Fig. 3C). Gene expression profile of HCN4-overexpressing cardiomyocytes was 30-times higher than that in non-overexpressing iPSC-CMs. There was no significant difference in
Fig. 2 Generation of HCN4-overexpressing human induced pluripotent stem cells (iPSCs). A Confirmation of transgene integration in the AAVS1 locus by PCR. The 2023-bp product means homologous recombination (HR) and the 2575-bp product means random integration. Clone #5 of HCN4/EGFP iPSCs and clone #11 of EGFP iPSCs were mainly used in this study. B Undifferentiated markers expressed in HCN4-overexpressing and non-overexpressing iPSCs. C EGFP and HCN4 expression in HCN4-overexpressing and non-overexpressing iPSCs. Scale bar is 100 µm
mRNA levels of MYL2, a myosin isoform expressed in the ventricle, NKX2-5, a transcription factor expressed in the ventricle and atria, and SCN5A, a sodium channel expressed in the ventricle and atria. Additionally, sinoatrial node markers (TBX3, TBX18, SHOX2) were not upregulated in HCN4-overexpressing iPSC-CMs (Fig. 4A). Protein expression of NKX2-5 and MLC2v was also checked with immunostaining (Fig. 4B).

**Enhancement of spontaneous firing in HCN4-overexpressing cardiomyocytes**

HCN4-overexpressing cardiomyocytes showed a significantly higher rates of spontaneous firing and beating than that in non-overexpressing cardiomyocytes: 13.2 ± 1.7/15 s versus 7.8 ± 0.8/15 s (Fig. 5A and B, (Additional files 4 and 5). Additionally, the frequency of spontaneous contraction was suppressed by ivabradine and was promoted by...
isoproterenol as shown in Fig. 5C: control, 10.8 ± 1.3/15 s ((Additional file 6); 10 µmol/L ivabradine, 4.1 ± 0.4/15 s (Additional file 7); 1 µmol/L isoproterenol, 17.0 ± 1.8/15 s (Additional file 8).

Enhanced pacing function by HCN4-overexpressing cardiomyocytes

To examine the pacing ability, HCN4-overexpressing or non-overexpressing EGFP-positive cardiomyocytes were cocultured with EGFP-negative cardiomyocytes from the parent iPSC line (Fig. 6A). EGFP-negative cardiomyocytes cocultured with HCN4-overexpressing cardiomyocytes showed a significantly higher beating frequency than that in EGFP-negative cardiomyocytes cocultured with non-overexpressing cardiomyocytes: 8.8 ± 0.5/15 s versus 4.0 ± 0.0/15 s (Fig. 6B, Additional files 9 and 10).

Discussion

In this study, we generated HCN4-overexpressing cardiomyocytes from human iPSCs, and showed that HCN4 overexpression in human cardiomyocytes evoked a higher spontaneous firing frequency than that of control cardiomyocytes, resulting in enhanced pacing function in vitro. iPSC-CMs are immature and lack $I_{K1}$ current to maintain quiescent membrane potential and have a relatively high maximal diastolic potential (−60 mV), which may not be sufficient to activate HCN channels [24]. However, a significant increase in $I_{K1}$ was observed in HCN4-overexpressing cardiomyocytes at −45 and −65 mV as shown in Fig. 3E. In addition, the spontaneous contraction frequency was suppressed by the HCN channel inhibitor ivabradine (Fig. 5C), suggesting that the enhancement of diastolic depolarization by increased $I_{K1}$ current caused by HCN4 overexpression led to an enhanced pacing effect of iPSC-CMs. So far, many groups, including us, have reported an increase in the frequency of spontaneous firing and the addition of a pacing function by transduction of HCN genes in mouse ESC-CMs, mesenchymal stem cells or the left ventricle [11, 25–32]. Results in this study are consistent with the findings of previous studies.

As previously reported [23, 33], it was possible to confirm long-term expression not only in iPSCs but also in iPSC-CMs by transduction of HCN4 into the AAVS1 safe harbor locus. We have also experienced loss of EGFP expression during differentiation in cardiomyocytes and non-cardiomyocytes derived from EGFP-positive iPSC lines without homologous recombination of the transgene (data was not shown).

HCN4-overexpressing cardiomyocytes were induced very efficiently since the commonly used efficient cardiac differentiation protocol using a GSK3 inhibitor and a Wnt inhibitor and the cardiomyocyte purification method can be applied [20, 21, 34]. Therefore, our strategy for generating cardiomyocytes with enhanced pacing function is simple and feasible compared to previously reported methods for generating sinoatrial node-like cells from human PSCs using complicated combinations of growth factors and compounds [4–8].

In the embryonic heart, HCN4 expression is first seen in the cardiac crescent, the source of the left ventricle and atria, and as it develops, it becomes localized to the conduction system, including the sinoatrial node [35, 36]. In our study, there was no significant upregulation of sinoatrial node marker genes or working myocyte marker genes in HCN4-overexpressing iPSC-CMs as far as we examined with qPCR. This suggests that constitutive HCN4 overexpression did not change the cardiomyocyte subtype into sinoatrial node-like cells. The proportions of ventricular, atrial and nodal type in human PSC-CMs vary depending on the differentiation protocols and cell lines [20, 37, 38]. That is, the baseline cardiomyocyte phenotype might affect the spontaneous firing frequency and pacing function also when HCN4 is overexpressed. For better integration between transplanted cells and the recipient myocardium, HCN4-overexpressing ventricular myocytes might be useful for transplantation into the ventricle, while HCN4-overexpressing atrial myocytes might be better for transplantation into the atria.

Study limitations

Only in vitro studies have been conducted. It has not been investigated how much pacing can be done in vivo. Since the connexin expression patterns are different between the atrium and ventricles or between healthy and diseased hearts [39], the pacing ability in vivo might be affected by various conditions.

The firing frequency probably depends on the expression level of transduced HCN4. Although EGFP expression was detected for more than 3 months in vitro in this study, the maintenance of transgene expression over a longer period should be checked, especially in vivo.

In addition, the possibility of tachycardia is a concern because some groups have reported that transplantation of a large number of pluripotent stem cell-derived cardiomyocytes transplanted into an infarcted heart resulted in ventricular tachyarrhythmias [40–42].

Fig. 4 Gene expression profile of HCN4-overexpressing human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). A Messenger RNA levels evaluated by quantitative polymerase chain reaction on differentiation day 30 (n = 4 in each) (The data are shown as means ± standard deviation.) B Nkx2-5 expression evaluated by immunostaining on day 35. C MLC2v expression evaluated by immunostaining on day 35. Scale bar is 100 µm.
Fig. 4 (See legend on previous page.)
However, it might be possible to control the pacing rate with drugs because spontaneous firing responded to an HCN channel inhibitor, ivabradine, in this study. Actually, Nakamura et al. also showed an anti-arrhythmic effect of ivabradine on iPSC-CM engraftment arrhythmias [43].

Cardiac Troponin I promoter-driven human HCN4 transgenic mice showed similar cardiac morphology at
birth but cardiac dilatation after birth due to dysregulation of calcium homeostasis and increased myocardial apoptosis [44]. Therefore, it is necessary to investigate the effect of long-term HCN4 overexpression on transplanted cells in vivo in the future.

Small animals such as mice and rats have a faster heart rate than humans (>350 bpm). Even if atrioventricular block is performed to create a bradycardia model, its heart rate is more than 120 bpm (Saito et al. Int Heart J. 2018), making it difficult to evaluate the pacing function of human cells. Therefore, in vivo studies need to use large animals such as monkeys or pigs that have been treated with immunosuppressive drugs. In addition, tumorigenic potential should be assessed.

**Conclusions**

We generated HCN4-overexpressing human iPSC-CMs showing enhancement of $I_f$ current and pacing ability. Application of these cells with added pacing function to a biological pacemaker is expected in the future.

**Abbreviations**

CAR: Chimeric antigen receptor; cTnT: Cardiac Troponin T; ESCs: Embryonic stem cells; ESC-CMs: Embryonic stem cell-derived cardiomyocytes; HCN channel: Hyperpolarization-activated cyclic nucleotide-gated potassium channel; iPSCs: Induced pluripotent stem cells; iPSC-CMs: Induced pluripotent stem cell-derived cardiomyocytes; PCR: Polymerase chain reaction; qPCR: Quantitative polymerase chain reaction; PSCs: Pluripotent stem cells; PSC-CMs: Pluripotent stem cell-derived cardiomyocytes; TEM: Transmission electron microscopy.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13287-022-02818-y.

Additional file 1: Differentiation of day 8 cardiomyocytes derived from HCN4-overexpressing human induced pluripotent stem cells.

Additional file 2: HCN4-overexpressing cardiomyocytes on differentiation day 103 (GFP).

Additional file 3: HCN4-overexpressing cardiomyocytes on differentiation day 103 (phase contrast).

Additional file 4: HCN4-overexpressing cardiomyocytes on day 27.

Additional file 5: Non-overexpressing cardiomyocytes on day 27.

Additional file 6: Drug response of HCN4-overexpressing cardiomyocytes (no treatment).

Additional file 7: Drug response of HCN4-overexpressing cardiomyocytes (10 µmol/L ivabradine).

Additional file 8: Drug response of HCN4-overexpressing cardiomyocytes (1 µmol/L isoproterenol).

Additional file 9: Parent cardiomyocytes paced by HCN4-overexpressing cardiomyocytes. The left half is HCN4-overexpressing cardiomyocytes and the right half is parental line-derived cardiomyocytes.

Additional file 10: Parent cardiomyocytes paced by non-overexpressing cardiomyocytes. The left half is non-overexpressing cardiomyocytes and the right half is parental line-derived cardiomyocytes.

**Acknowledgements**

The authors are grateful to Kaoru Akazawa, Megumi Kondo and Masayo Ohmori for their excellent assistance.

**Authors’ contributions**

YS designed the research, performed all of the experiments, analyzed the data and drafted the manuscript. KN conceived the idea, obtained permission...
from the Institutional Review Board for this study, interpreted the data and wrote the manuscript. MY contributed to experiments for generating human iPSC line and subcloning. HS contributed to patch clamp experiments. SA contributed to data interpretation. TM contributed to data interpretation. HI contributed to data interpretation and financial support. All authors read and approved the final version of this manuscript.

Funding
This work was supported by JSPS KAKENHI Grant Number JP16K19407.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences (approval number: Ge299), and written informed consent was obtained from the healthy subject before the procedure. No new human iPSC line was made from fibroblasts for this study. The investigation also conformed to the principles outlined in the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Author details
1 Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Density, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, 2-5-1 Shikata-cho, 700-8558 Kita-ku, Okayama, Japan. 2 Department of Chronic Kidney Disease and Cardiovascular Disease, Dentistry, and Pharmaceutical Science, Okayama University Graduate School of Medicine, Okayama, Japan. 3 Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, Japan. 4 Department of Cardiovascular Therapeutics, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.

Received: 27 December 2021 Accepted: 20 March 2022 Published online: 01 April 2022

References

1. Kapoor N, Liang W, Marbán E, Cho HC. Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx1. Nat Biotechnol. 2013;31(1):54–62.
2. Hu FF, Dawkins JF, Cho HC, Marbán E, Cingolani E. Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Sci Transl Med. 2014;6(249):245–44.
3. Yechikov S, Kao HKJ, Chang CW, Pretto D, Zhang XD, Sun YH, et al. NODAL inhibition promotes differentiation of pacemaker-like cardiomyocytes from human induced pluripotent stem cells. Stem Cell Res. 2020;49:102043.
4. Protze SI, Liu J, Nussinovitch UJ, Ohana L, Baxx PH, Gepstein L, et al. Sinusoidal node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker. Nat Biotechnol. 2017;35(1):56–68.
5. Liu F, Fang Y, Hou X, Yan Y, Xiao H, Zuo D, et al. Enrichment differentiation of human induced pluripotent stem cells into sinusoidal node-like cells by combined modulation of BMP, FGF, and RA signaling pathways. Stem Cell Res Ther. 2020;11(1):284.
6. Liang W, Han P, Kim EH, Mak J, Zhang R, Torrente AG, et al. Canonical Wnt signaling promotes pacemaker cell specification of cardiac mesodermal cells derived from mouse and human embryonic stem cells. Stem Cells. 2020;38(3):352–68.
7. Peszhoiman A, Engel JL, Nguyen NB, Skelton RJP, Gilmore WB, Qiao R, et al. Isolation and characterization of HESC-derived heart field-specific cardiomyocytes unravels new insights into their transcriptional and electrophysiological profiles. Cardiovasc Res. 2021.
8. Zhao H, Wang F, Zhang W, Yang M, Tang Y, Wang X, et al. Overexpression of TBX3 in human induced pluripotent stem cells (hiPSCs) increases their differentiation into cardiac pacemaker-like cells. Biomed Pharmacother. 2020;130:110612.
9. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CART cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–67.
10. Guijak F, Pfeiderholt L, Ross AK, Choi YR, Collins K, Nims RJ, et al. Designer stem cells: genome engineering and the next generation of cell-based therapies. J Orthop Res. 2019;37(6):1287–93.
11. Saito Y, Nakamura K, Yoshida M, Sugiyama H, Ohe T, Kurokawa J, et al. Enhancement of spontaneous activity by HCN4 overexpression in mouse embryonic stem cell-derived cardiomyocytes: a possible biological pacemaker. PLOS ONE. 2015;10(9):e0138193.
12. Saito Y, Nakamura K, Yoshida M, Sugiyama H, Takano M, Nasage S, et al. HCN4-Overexpressing mouse embryonic stem cell-derived cardiomyocytes generate a new rapid rhythm in rats with bradycardia. Int Heart J. 2018;59(3):601–6.
13. Kehat I, Khimovich L, Caspi O, Gepstein A, Shoffit R, Arbel G, et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol. 2004;22(10):1282–9.
14. Chauveau S, Anuykhoovsky EP, Ben-Ari M, Naor S, Jiang YP, Danilo P, et al. Induced pluripotent stem cell-derived cardiomyocytes provide in vivo biological pacemaker function. Circ Arrhythm Electrophysiol. 2017;10(5):e004508.
15. Ichimura H, Kadota S, Kashihara T, Yamada M, Ito K, Kobayashi H, et al. Increased predominance of the matured ventricular subtype in embryonic stem cell-derived cardiomyocytes in vivo. Sci Rep. 2020;10(1):11883.
16. Yang X, Pabon L, Munry CE. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res. 2014;114(3):151–23.
17. Odening KE, Gomez AM, Dobrev D, Fabritz L, Heinzl FR, Mangoni ME, et al. ESC working group on cardiac cellular electrophysiology position paper: relevance, opportunities, and limitations of experimental models for cardiac electrophysiology research. Europace. 2021;23(11):795–814.
18. Saito Y, Nakamura K, Nishi N, Iigawa O, Yoshida M, Miyoshi T, et al. TRPM4 mutation in patients with ventricular noncompaction and cardiac conduction disease. Circ Genom Precis Med. 2018;11(5):e002103.
19. Nakagawa M, Taniguchi Y, Senda S, Tazakiwa N, Ichisaka T, Asano K, et al. A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Sci Rep. 2014;4:3594.
20. Lian X, Hsiao C, Wilson G, Zhu K, Hazelhine LB, Azarrin SM, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci USA. 2012;109(27):E1848–57.
21. Tóthyama S, Hattori F, Sano M, Hishiki T, Nagahata Y, Matsura T, et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell. 2013;3(1):127–37.
22. Diekelker RC, Choi VM, Moehle EA, Paschon DE, Hockemeyer D, Meising SH, et al. Functional genomic, proteomic, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res. 2010;20(8):1133–42.
23. Wang Y, Zhang Y, Hu S, Lan F, Lee AS, Huber B, et al. Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc-finger nucleases for cellular imaging. Circ Res. 2012;111(12):1494–503.
24. Vassalle M. The pacemaker current (I(f)) does not play an important role in regulating SA node pacemaker activity. Cardiovasc Res. 1995;30(2):309–10.
25. Potapova I, Piotnikov A, Lu Z, Danilo P, Jalilova Y, Qu J, et al. Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers. Circ Res. 2004;94(7):952–9.
26. Plotnikov AN, Shlapakov I, Szabolcs M J, Danilo P Jr, Loret B, Potapova IA, et al. Xenografted adult human mesenchymal stem cells provide a platform for sustained biological pacemaker function in canine heart. Circulation. 2007;116(7):706–13.

27. Zhang Z, Song Z, Cheng J, Nong Y, Wei L, Zhang C. The integration and functional evaluation of rabbit pacing cells transplanted into the left ventricular free wall. Int J Med Sci. 2012;9(7):513–20.

28. Nong Y, Zhang C, Wei L, Zhang Z, Cheng J, Wen L, et al. In situ investigation of allografted mouse HCN4 gene-transfected rat bone marrow mesenchymal stromal cells with the use of patch-clamp recording of ventricular slices. Cytotherapy. 2013;15(8):905–19.

29. Oishi K, Itoh M, Hirashima S, Kuwabara Y, Ishihara K, Kuwahara K, et al. Ectopic automaticity induced in ventricular myocytes by transgenic overexpression of HCN2. J Mol Cell Cardiol. 2013;80:81–9.

30. Tse HF, Xue T, Lau CP, Sui CW, Wang K, Zhang QY, et al. Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation. 2006;114(10):1000–10.

31. Cai J, Yi FF, Li YH, Yang XC, Song J, Jiang XJ, et al. Adenoviral gene transfer of HCN4 creates a genetic pacemaker in pigs with complete atrioventricular block. Life Sci. 2007;80(19):1746–53.

32. Boink GJ, Duan L, Nearing BD, Shlapakova IN, Sosunov EA, Anyukhovsky EP, et al. HCN2/SkM1 gene transfer into canine left bundle branch induces stable, autonomously responsive pacing at physiological heart rates. J Am Coll Cardiol. 2013;61(11):1192–201.

33. Luo Y, Liu C, Cerbini T, San H, Liu Y, Chen G, et al. Stable enhanced green fluorescent protein expression after differentiation and transplantation of reporter human induced pluripotent stem cells generated by AAV51 transcription activator-like effector nucleases. Stem Cells Transl Med. 2014;3(7):821–35.

34. Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD, et al. Chemically defined generation of human cardiomyocytes. Nat Methods. 2014;11(8):855–60.

35. Liang X, Wang G, Lin L, Lowe J, Zhang Q, Bu L, et al. HCN4 dynamically marks the first heart field and conduction system precursors. Circ Res. 2013;113(4):399–407.

36. Später D, Abramczuk MK, Buac K, Zangi L, Stachel MW, Clarke J, et al. HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells. Nat Cell Biol. 2013;15(9):1098–106.

37. Lee JH, Protze SI, Laksmi Z, Backx PH, Keller GM. Human pluripotent stem cell-derived atrial and ventricular cardiomyocytes develop from distinct mesoderm populations. Cell Stem Cell. 2017;21(2):179–94.e4.

38. Zhang J, Klos M, Wilson GF, Herman AM, Lian X, Raval KK, et al. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res. 2012;110(9):1125–36.

39. Severs NJ, Bruce AF, Dupont E, Rotrey S. Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res. 2008;80(1):9–19.

40. Romagnuolo R, Masoudpour H, Porta-Sánchez A, Qi L, Barry J, Laskary A, et al. Human embryonic stem cell-derived cardiomyocytes regenerate the infarcted pig heart but induce ventricular tachyarrhythmias. Stem Cell Rep. 2019;12(5):967–81.

41. Shiba Y, Gomibuchi T, Seto T, Wada Y, Ichimura H, Tanaka Y, et al. Allogeneic transplantation of iPSC-derived cardiomyocytes regenerates primate hearts. Nature. 2016;538(7625):388–91.

42. Liu YW, Chen B, Yang X, Fugate JA, Kalucki FA, Futakuchi-Tsuchida A, et al. Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. Nat Biotechnol. 2018;36(7):597–605.

43. Nakamura K, Neidig LE, Yang X, Weber GJ, El-Nachef D, Tsuchida H, et al. Pharmacologic therapy for engraftment arrhythmia induced by transplantation of human cardiomyocytes. Stem Cell Rep. 2021;16(10):2473–87.

44. Yampolsky P, Koene M, Mosquera M, Geschwill P, Nauck S, Witzenberger M, et al. Augmentation of myocardial I(f ) dysregulates calcium homeostasis and causes adverse cardiac remodeling. Nat Commun. 2019;10(1):3295.